Limited sustained response and lack of HBsAg decline after stopping long-term nucleos(t)ide analogue therapy in HBeAg negative patients with chronic hepatitis B: Results of the prospective, randomized, open-label phase IV STOP study

Conference Reports for NATAP

20th International Workshop
on Clinical Pharmacology of HIV
Hepatitis & Other Antiviral Drugs
May 14-16, 2019. Noordwijk, the Netherlands


Limited sustained response and lack of HBsAg decline after stopping long-term nucleos(t)ide analogue therapy in HBeAg negative patients with chronic hepatitis B: Results of the prospective, randomized, open-label phase IV STOP study

	Reported by Jules Levin AASLD 2018